SER logo

Serina Therapeutics NYSEAM:SER Stock Report

Last Price

US$4.90

Market Cap

US$46.8m

7D

-2.0%

1Y

n/a

Updated

21 Nov, 2024

Data

Company Financials

Serina Therapeutics, Inc.

NYSEAM:SER Stock Report

Market Cap: US$46.8m

SER Stock Overview

A biotechnology company, develops drugs to treat neurological diseases and pain. More details

SER fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Serina Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Serina Therapeutics
Historical stock prices
Current Share PriceUS$4.90
52 Week HighUS$19.93
52 Week LowUS$3.81
Beta0
11 Month Change-35.95%
3 Month Change-41.74%
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-67.05%

Recent News & Updates

Recent updates

Shareholder Returns

SERUS BiotechsUS Market
7D-2.0%-6.5%-1.0%
1Yn/a14.6%30.3%

Return vs Industry: Insufficient data to determine how SER performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how SER performed against the US Market.

Price Volatility

Is SER's price volatile compared to industry and market?
SER volatility
SER Average Weekly Movement15.3%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: SER's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SER's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200610Steve Ledgerserinatherapeutics.com

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy.

Serina Therapeutics, Inc. Fundamentals Summary

How do Serina Therapeutics's earnings and revenue compare to its market cap?
SER fundamental statistics
Market capUS$46.77m
Earnings (TTM)-US$7.35m
Revenue (TTM)US$3.16m

13.8x

P/S Ratio

-5.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SER income statement (TTM)
RevenueUS$3.16m
Cost of RevenueUS$6.02m
Gross Profit-US$2.86m
Other ExpensesUS$4.49m
Earnings-US$7.35m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.83
Gross Margin-90.70%
Net Profit Margin-232.75%
Debt/Equity Ratio-80.7%

How did SER perform over the long term?

See historical performance and comparison